

Yann Godet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9104542/publications.pdf>

Version: 2024-02-01

18
papers

457
citations

759233

12
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

694
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response. <i>Clinical Cancer Research</i> , 2012, 18, 2943-2953.	7.0	97
2	Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor. <i>Clinical Cancer Research</i> , 2012, 18, 6284-6295.	7.0	54
3	Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. <i>Vaccines</i> , 2015, 3, 490-502.	4.4	43
4	Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity. <i>Cancer Research</i> , 2016, 76, 4100-4112.	0.9	42
5	CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin. <i>International Journal of Cancer</i> , 2019, 145, 3112-3125.	5.1	32
6	CD20 alternative splicing isoform generates immunogenic CD4 helper T cell epitopes. <i>International Journal of Cancer</i> , 2015, 137, 116-126.	5.1	29
7	Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 260.	3.7	26
8	Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4 ⁺ Th1 responses against telomerase in cancer patients. <i>Oncolmmunology</i> , 2016, 5, e1137416.	4.6	21
9	Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1073-1077.	3.3	20
10	Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination. <i>Oncolmmunology</i> , 2013, 2, e23430.	4.6	17
11	New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. <i>Experimental Hematology and Oncology</i> , 2015, 5, 7.	5.0	17
12	Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells. <i>Journal of Immunology</i> , 2016, 197, 1597-1608.	0.8	16
13	Naturally Occurring Telomerase-Specific CD4 T-Cell Immunity in Melanoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 435-444.	0.7	15
14	Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy. <i>Human Gene Therapy</i> , 2018, 29, 1202-1212.	2.7	8
15	Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T Cells. <i>Cancers</i> , 2022, 14, 3168.	3.7	8
16	An unmet need: Harmonization of IL-7 and IL-15 combination for the ex vivo generation of minimally differentiated T cells. <i>Cellular Immunology</i> , 2021, 363, 104314.	3.0	5
17	Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice. <i>Oncotarget</i> , 2017, 8, 48959-48971.	1.8	5
18	Homeostatic cytokines tune naivety and stemness of cord blood-derived transgenic T cells. <i>Cancer Gene Therapy</i> , 2021, . .	4.6	2